McKesson Corporation (MCK)
After hours:
| Previous close | 482.27 |
| Open | 482.70 |
| Bid | 480.00 x 1400 |
| Ask | 490.00 x 800 |
| Day's range | 480.49 - 485.42 |
| 52-week range | 431.35 - 637.51 |
| Volume | |
| Avg. volume | 1,018,426 |
| Market cap | 62.948B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 21.69 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.84 (0.59%) |
| Ex-dividend date | 30 Aug 2024 |
| 1y target est | N/A |
- Business Wire
McKesson Corporation Announces Second Quarter Fiscal 2025 Earnings Release Date
IRVING, Texas, September 23, 2024--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.
- Business Wire
McKesson Corporation Announces Sale of Rexall and Well.ca Businesses to Birch Hill Equity Partners
IRVING, Texas, September 05, 2024--McKesson Corporation (NYSE: MCK) announced today that it has signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm.
- Business Wire
McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute’s Core Ventures
IRVING, Texas, August 26, 2024--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core
